Eloxx Pharmaceuticals, Inc. (ELOX) Stock Price & Analysis
Eloxx Pharmaceuticals, Inc. (ELOX) rose 5.71% to USD 15 as of September 8, 2026 at 07:00 UTC, according to Nexqual real-time market data.
ELOX last closed at USD 15; the session ranged USD 14.1–16.48 on volume of 38,842 shares. Market capitalization is —, with a 52-week range of USD 8.2–23.4 (NCM). Source: Nexqual, September 8, 2026 at 07:00 UTC.
Key Statistics (as of September 8, 2026 at 07:00 UTC)
| Price | USD 15 |
|---|---|
| Change | ▲ 5.71% (up) |
| Previous Close | USD 15 |
| Open | USD 15 |
| Day Range | USD 14.1 – 16.48 |
| 52-Week Range | USD 8.2 – 23.4 |
| Volume | 38,842 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (ELOX)
Nexqual's technical model rates ELOX "SELL" based on 1 bullish and 5 bearish signals across 62 daily candles, as of September 8, 2026 at 07:00 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 46.74 (neutral) |
| vs SMA50 | Below (USD 15) |
| MACD | -0.13 (negative) |
From Eloxx Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-03-17)
Key Strengths & Strategy (as disclosed to the SEC)
- Even if we succeed in bringing one or more products to the market, these products may not be considered cost-effective, and the amount reimbursed for any products may be insufficient to allow us to sell our products on a competitive basis.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| EVLO | Evelo Biosciences, Inc. | USD 0 | ▲ 0% |
| CYCN | Cyclerion Therapeutics, Inc. | USD 4.25 | ▲ 0% |
| ATXI | Avenue Therapeutics, Inc. | USD 0.54 | ▼ 4.56% |
| ARDS | Aridis Pharmaceuticals Inc. | USD 0 | ▲ 0% |
| SYBX | Synlogic, Inc. | USD 1.17 | ▼ 4.1% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 07:00 UTC. This page is informational and not investment advice.